Načítá se...
Prolonged First-Dose Hypotension Induced by Sacubitril/Valsartan
Entresto was recommanded by major guidelines as the frontline therapy for heart failure with reduced ejection fraction since its clinical benefit was proved by the PARADIGM-HF trial. Angiotensin converting enzyme inhibitors are the cornerstone of the treatment of HF. Varying incidences of first-dose...
Uloženo v:
| Vydáno v: | Acta Cardiol Sin |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taiwan Society of Cardiology
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5777949/ https://ncbi.nlm.nih.gov/pubmed/29375230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6515/ACS.201801_34(1).20170614A |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|